Hybrid immunity and strategies for COVID-19 vaccination.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

24 citing papers in PubMed.

1. A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS‑CoV‑2.Journal of nanobiotechnology · 2026
   Article
2. Maternal immunization status and SARS-CoV-2 antibody transfer to neonates at birth.Frontiers in pediatrics · 2026
   Article
3. Hybrid immunity strategies: heterologous vaccination combined with natural SARS-CoV-2 infection.Frontiers in medicine · 2026
   Review
4. Two-Year Follow-Up of Humoral and Cellular Immune Responses to SARS-CoV-2 in Healthcare Professionals.Vaccines · 2025
   Article
5. Third exposure to COVID-19 infection or vaccination differentially impacts T cell responses.The Journal of infection · 2025
   Observational
6. Clinical and immunological insights into SARS-CoV-2 reinfection: a propensity score-matched cohort study.BMC infectious diseases · 2025
   Article
7. Did COVID-19 surveillance system sensitivity change after Omicron? a retrospective observational study in England.BMC infectious diseases · 2025
   Observational
8. The Second Round of a Population-Based Seroprevalence Study of Anti-SARS-CoV-2 Antibodies and COVID-19 Vaccination Assessment in the Republika Srpska, Bosnia and Herzegovina.Influenza and other respiratory viruses · 2025
   Article
9. Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine.Human vaccines & immunotherapeutics · 2024
   Review
10. Factors Predicting COVID-19 Vaccine Effectiveness and Longevity of Humoral Immune Responses.Vaccines · 2024
    Review
11. How effective is the BNT162b2 mRNA vaccine against SARS-CoV-2 transmission and infection? A national programme analysis in Monaco, July 2021 to September 2022.BMC medicine · 2024
    Article
12. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity.NPJ vaccines · 2024
    Article
13. Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan.The Lancet regional health. Western Pacific · 2023
    Article
14. The effectiveness of primary series CoronaVac vaccine in preventing COVID-19 illness: A prospective cohort study among healthcare workers in Azerbaijan, May-November 2021.Influenza and other respiratory viruses · 2023
    Article
15. Impact of prior SARS-COV-2 infection and vaccination on COVID-19 hospital admission and mortality amongst nursing home residents.Aging clinical and experimental research · 2023
    Article
16. Trajectory of Spike-Specific B Cells Elicited by Two Doses of BNT162b2 mRNA Vaccine.Cells · 2023
    Article
17. An insight overview on COVID-19 mRNA vaccines: Advantageous, pharmacology, mechanism of action, and prospective considerations.International immunopharmacology · 2023
    Review
18. Projection of COVID-19 Positive Cases Considering Hybrid Immunity: Case Study in Tokyo.Vaccines · 2023
    Article
19. Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults.Infectious disease clinics of North America · 2023
    Review
20. Epidemiological and clinical characteristics of COVID-19 reinfection during the epidemic period in Yangzhou city, Jiangsu province.Frontiers in public health · 2023
    Article

Corrections and comments

• Comment on
  Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.2023

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as